Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TRDA

Entrada Therapeutics Inc

Apr 18 • 04:00PM ET

11.91

Dollar change -0.31
Percentage change -2.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF AVUV IWN VTWO SCHA IWC VHT EES

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	46.49%	Shs Outstand	33.44M	Perf Week	-10.18%
Market Cap	400.18M	Forward P/E	-	EPS next Y	-3.48	Insider Trans	-0.05%	Shs Float	17.98M	Perf Month	-6.22%
Income	-6.68M	PEG	-	EPS next Q	-0.59	Inst Own	47.87%	Short Float	9.82%	Perf Quarter	-20.55%
Sales	129.01M	P/S	3.10	EPS this Y	-1152.00%	Inst Trans	-0.82%	Short Ratio	23.13	Perf Half Y	-23.26%
Book/sh	7.25	P/B	1.64	EPS next Y	-38.78%	ROA	-1.85%	Short Interest	1.77M	Perf Year	-22.26%
Cash/sh	10.48	P/C	1.14	EPS next 5Y	-	ROE	-2.94%	52W Range	10.62 - 18.44	Perf YTD	-21.07%
Dividend Est.	-	P/FCF	2.98	EPS past 5Y	-5.52%	ROI	-2.21%	52W High	-35.41%	Beta	-0.39
Dividend TTM	-	Quick Ratio	2.33	Sales past 5Y	0.00%	Gross Margin	97.85%	52W Low	12.15%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	2.33	EPS Y/Y TTM	93.10%	Oper. Margin	-2.45%	RSI (14)	36.40	Volatility	5.48% 6.01%
Employees	159	Debt/Eq	0.28	Sales Y/Y TTM	-	Profit Margin	-5.18%	Recom	1.00	Target Price	21.00
Option/Short	No / Yes	LT Debt/Eq	0.25	EPS Q/Q	63.59%	Payout	-	Rel Volume	1.71	Prev Close	12.22
Sales Surprise	76.62%	EPS Surprise	-72.21%	Sales Q/Q	-	Earnings	Mar 13 BMO	Avg Volume	76.36K	Price	11.91
SMA20	-11.33%	SMA50	-10.98%	SMA200	-19.54%	Trades		Volume	130,286	Change	-2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
07:00AM	Loading…
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
07:00AM	Loading…
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
07:00AM	Loading…
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%
May-12-22 07:00AM	Entrada Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.25%
May-11-22 09:30AM	Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022 (GlobeNewswire) -9.44%
May-10-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.84%
Mar-15-22 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +9.78%
Feb-23-22 08:00AM	Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference (GlobeNewswire) -17.21%
Feb-04-22 01:27PM	We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth (Simply Wall St.) +12.79%
Feb-03-22 09:38AM	5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ... (GuruFocus.com)
Jan-05-22 08:00AM	Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel (GlobeNewswire) -15.44%
Dec-17-21 08:00AM	Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Dec-09-21 07:00AM	Entrada Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-18-21 08:00AM	Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-05-21 08:32AM	4 Stocks Insiders Are Buying (Benzinga)
Nov-02-21 04:26PM	Entrada Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +13.19%
Oct-28-21 10:21PM	Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIM PETER S	Director	Apr 08 '24	Buy	13.57	2,600	35,290	62,936	Apr 10 04:35 PM
KIM PETER S	Director	Mar 28 '24	Buy	13.75	1,512	20,794	60,336	Apr 01 04:31 PM
KIM PETER S	Director	Mar 26 '24	Buy	13.64	2,750	37,509	58,824	Mar 26 05:57 PM
KIM PETER S	Director	Mar 25 '24	Buy	13.36	3,180	42,472	56,074	Mar 26 05:57 PM
KIM PETER S	Director	Mar 22 '24	Buy	13.76	3,118	42,901	52,894	Mar 26 05:57 PM
KIM PETER S	Director	Mar 21 '24	Buy	13.24	704	9,318	49,776	Mar 21 04:31 PM
KIM PETER S	Director	Mar 20 '24	Buy	12.66	1,128	14,281	49,072	Mar 21 04:31 PM
KIM PETER S	Director	Mar 19 '24	Buy	12.66	900	11,397	47,944	Mar 21 04:31 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 15 '24	Option Exercise	2.10	9,000	18,900	83,170	Mar 19 04:33 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 06 '24	Sale	12.31	4,086	50,285	74,170	Mar 08 04:36 PM
Dowden Nathan J	President & COO	Mar 06 '24	Sale	12.32	1,826	22,499	137,204	Mar 08 04:34 PM
Doshi Dipal	CEO	Feb 15 '24	Sale	15.00	1,000	15,000	243,279	Feb 20 04:37 PM
Doshi Dipal	CEO	Jan 16 '24	Sale	15.99	1,000	15,990	244,279	Jan 18 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Option Exercise	2.10	94	197	49,665	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Sale	16.67	94	1,567	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Option Exercise	2.10	10,206	21,433	59,777	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Sale	15.69	10,206	160,124	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Option Exercise	2.10	2,200	4,620	51,771	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Sale	15.07	2,200	33,155	49,571	Dec 26 04:35 PM
Doshi Dipal	President and CEO	Dec 20 '23	Sale	15.00	1,000	15,000	245,279	Dec 22 04:38 PM
Doshi Dipal	President and CEO	Nov 13 '23	Sale	16.23	1,000	16,230	246,279	Nov 13 04:35 PM
Doshi Dipal	President and CEO	Oct 17 '23	Sale	15.00	1,000	15,000	247,279	Oct 19 05:27 PM
Doshi Dipal	President and CEO	Sep 13 '23	Sale	15.00	1,000	15,000	248,279	Sep 15 04:21 PM
Dowden Nathan J	Chief Operating Officer	Sep 06 '23	Sale	13.47	972	13,089	48,168	Sep 06 05:07 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 06 '23	Sale	13.48	950	12,806	49,571	Sep 06 05:11 PM
KREHER NERISSA	Chief Medical Officer	Sep 06 '23	Sale	13.48	892	12,022	40,037	Sep 06 05:08 PM
Doshi Dipal	President and CEO	Aug 14 '23	Sale	15.67	1,000	15,671	201,069	Aug 16 04:32 PM
KREHER NERISSA	Chief Medical Officer	Aug 04 '23	Option Exercise	2.10	6,898	14,486	34,028	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 04 '23	Sale	14.14	6,898	97,521	27,130	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 03 '23	Option Exercise	2.10	9,464	19,874	36,594	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 03 '23	Sale	14.74	9,464	139,530	27,130	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 02 '23	Option Exercise	2.10	10,348	21,731	37,478	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 02 '23	Sale	15.19	10,348	157,168	27,130	Aug 04 04:50 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 11 '23	Option Exercise	2.10	3,884	8,156	40,631	Jul 12 04:34 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 11 '23	Sale	18.04	14,852	267,915	153,447	Jul 12 04:32 PM
Dowden Nathan J	Chief Operating Officer	Jul 11 '23	Sale	18.05	3,897	70,333	35,376	Jul 12 04:33 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 11 '23	Sale	18.00	3,884	69,904	36,747	Jul 12 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 10 '23	Option Exercise	2.10	6,116	12,844	42,863	Jul 12 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 10 '23	Sale	17.98	6,116	109,958	36,747	Jul 12 04:34 PM
Dowden Nathan J	Chief Operating Officer	Jul 10 '23	Sale	18.00	3,200	57,605	39,273	Jul 12 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 10 '23	Sale	18.00	3,026	54,474	168,299	Jul 12 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jun 29 '23	Option Exercise	2.10	8,790	18,459	36,747	Jun 30 04:32 PM
Dowden Nathan J	Chief Operating Officer	Jun 22 '23	Sale	16.02	7,097	113,700	42,473	Jun 22 04:46 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jun 21 '23	Option Exercise	2.10	17,500	36,750	45,457	Jun 23 04:20 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jun 21 '23	Sale	15.01	17,500	262,648	27,957	Jun 23 04:20 PM
Dowden Nathan J	Chief Operating Officer	Jun 20 '23	Sale	14.94	8,885	132,704	49,570	Jun 22 04:46 PM
Doshi Dipal	President and CEO	Apr 27 '23	Sale	13.71	2,000	27,422	202,069	May 01 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience